B-cell Lymphoma Recurrent Clinical Trial
The aim of this study is the safety and efficacy of Rituximab plus NK immunotherapy to recurrent B lymphoma.
By enrolling patients with B lymphoma adapted to enrolled criteria, this study will document
for the first time the safety and the short and long term efficacy of the combined therapy
using Rituximab and natural killer (NK) cells.
The safety will be evaluated by statistics of adverse reactions. The efficacy will be
evaluated according to local relief degree, progress free survival (PFS) and overall survival
(OS).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03664635 -
MB-CART20.1 Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03853616 -
MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT04303247 -
CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL
|
Early Phase 1 | |
| Recruiting |
NCT05318963 -
Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma
|
Phase 1 | |
| Recruiting |
NCT06378190 -
Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04531046 -
Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation
|
Phase 2 | |
| Not yet recruiting |
NCT05705570 -
A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies
|
Phase 1 | |
| Active, not recruiting |
NCT04304040 -
A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05909098 -
Safety and Efficacy of Autologous NK Cell Adjuvant Therapy for Relapsed/Refractory Non-Hodgkin's B-cell Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04747093 -
Induced-T Cell Like NK Cells for B Cell Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT05130489 -
CAR T Cell Therapy Related Cardiovascular Outcomes
|
||
| Active, not recruiting |
NCT04214886 -
CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies
|
Phase 1 | |
| Recruiting |
NCT03757000 -
A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies
|
Phase 1 |